SCHEDULE: Adage Capital Management Discloses Stake in Milestone Pharmaceuticals

Adage Capital Management, L.P. has reported beneficial ownership of 8,000,000 common shares of Milestone Pharmaceuticals Inc., representing 6.37% of the class, primarily through warrants.

Summary

• Adage Capital Management, L.P. (ACM), through its affiliate Adage Capital Partners, L.P. (ACP), has disclosed beneficial ownership of 8,000,000 common shares of Milestone Pharmaceuticals Inc.
• This holding represents 6.37% of the outstanding common shares.
• The shares are issuable upon the exercise of warrants directly held by ACP.
• Robert Atchinson and Phillip Gross, as managing members of entities related to ACM and ACP, are also reporting persons.
• The filing is an amendment to a Schedule 13G, indicating a passive investment stake.
• The reporting date for the event requiring this filing is March 31, 2026.
• The total number of outstanding common shares used for the percentage calculation is 117,667,277 as of March 20, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a known asset manager, but it is a passive disclosure and not an operational update from the company itself.

Positives

• Adage Capital Management has taken a significant stake (6.37%) in Milestone Pharmaceuticals, which could signal confidence in the company's future prospects.
• The investment is structured through warrants, suggesting a potentially favorable entry point or a belief in the company's ability to execute and increase its share value.

Negatives

• The filing does not contain any negative financial results or operational challenges; it is purely a disclosure of beneficial ownership.

Risks

• The primary risk is associated with the exercise of warrants and the potential volatility of Milestone Pharmaceuticals' stock price, as the value of the investment is tied to the company's performance and market conditions.
• There is a risk that the warrants may not be exercised if the stock price does not reach a favorable level, or if the company's outlook deteriorates.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Milestone Pharmaceuticals. Adage Capital Management's investment through warrants implies a positive outlook on the potential future value of Milestone Pharmaceuticals' common shares.

Management Comments

• The filing states: 'The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.'
• It also notes: 'Reflects Common Shares (as defined in Item 2(a)) issuable upon exercise of warrants.'

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors taking passive stakes in public companies. Adage Capital Management's disclosure indicates a significant, but non-controlling, interest in Milestone Pharmaceuticals, likely as part of a broader investment strategy in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May view the investment by Adage Capital Management as a positive signal, potentially increasing demand for the stock.
• Creditors: The filing does not directly impact creditors, but the company's overall financial health, which influences its ability to repay debt, is indirectly relevant.
• Employees: A stable or growing investor base can contribute to company stability and future growth opportunities.

Next Steps

• Milestone Pharmaceuticals may see increased investor interest due to the disclosure of Adage Capital Management's stake.
• Adage Capital Management will continue to monitor Milestone Pharmaceuticals' performance and may exercise its warrants if deemed advantageous.

Key Dates

Recommendation

This filing is a passive ownership disclosure and does not provide operational or financial performance data for Milestone Pharmaceuticals. While the significant stake by Adage Capital Management is a positive indicator of institutional interest, it does not offer sufficient information to warrant a buy or sell recommendation without further analysis of the company's underlying business and prospects.

Keywords

Milestone Pharmaceuticals, Schedule 13G, Adage Capital Management, Beneficial Ownership, Warrants, SEC Filing, Investment, Common Shares, Robert Atchinson, Phillip Gross